• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020.2019 年 3 月至 2020 年 12 月，抗生素耐药实验室网络中金属-β-内酰胺酶产生菌的阿兹仑司他-阿维巴坦药敏测试项目。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0048621. doi: 10.1128/AAC.00486-21.
2
Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against isolates.评估肉汤纸片洗脱法测定头孢他啶/阿维巴坦联合氨曲南对 分离株的药敏结果。
Microbiol Spectr. 2024 Oct 3;12(10):e0095324. doi: 10.1128/spectrum.00953-24. Epub 2024 Sep 3.
3
Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.2012 年至 2015 年期间，作为国际最佳耐药监测网络（INFORM）全球监测项目的一部分，分离出携带 OXA-48 酶的肠杆菌科细菌，对头孢他啶-阿维巴坦和氨曲南-阿维巴坦的活性进行评估。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00592-18. Print 2018 Dec.
4
Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).头孢地尔罗与新型β-内酰胺类-β-内酰胺酶抑制剂联合制剂对产金属β-内酰胺酶革兰氏阴性杆菌的活性：一项为期两年（2019-2020 年）研究的见解。
J Chemother. 2023 May;35(3):198-204. doi: 10.1080/1120009X.2022.2090615. Epub 2022 Jun 22.
5
Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales.评估头孢他啶对产超广谱β-内酰胺酶肠杆菌科高度耐药菌株中阿维巴坦/头孢他啶药敏试验的体外影响。
J Antimicrob Chemother. 2021 Mar 12;76(4):979-983. doi: 10.1093/jac/dkaa531.
6
In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China.中国多中心研究：注射用氨曲南-阿维巴坦对产金属β-内酰胺酶肠杆菌科细菌的体外活性。
Int J Infect Dis. 2020 Aug;97:11-18. doi: 10.1016/j.ijid.2020.05.075. Epub 2020 May 28.
7
Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.头孢他啶-阿维巴坦联合氨曲南对产丝氨酸和金属β-内酰胺酶铜绿假单胞菌的活性。
Diagn Microbiol Infect Dis. 2021 Jan;99(1):115227. doi: 10.1016/j.diagmicrobio.2020.115227. Epub 2020 Sep 28.
8
In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era.产金属β-内酰胺酶的生物体中头孢他啶-阿维巴坦与氨曲南联合药敏试验方法：联合药物在抗生素耐药时代的作用。
J Antibiot (Tokyo). 2022 Aug;75(8):454-462. doi: 10.1038/s41429-022-00537-3. Epub 2022 Jun 17.
9
Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).在欧洲、拉丁美洲和亚太地区（2020-2022 年）收集的对最近批准的β-内酰胺酶抑制剂组合耐药的肠杆菌科的阿维巴坦-阿唑巴坦活性。
Int J Antimicrob Agents. 2024 Apr;63(4):107113. doi: 10.1016/j.ijantimicag.2024.107113. Epub 2024 Feb 12.
10
In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.2019-2021 年 ATLAS 全球监测计划在拉丁美洲、非洲/中东、亚洲和欧亚地区收集的肠杆菌科分离株中，阿维巴坦-阿唑巴坦对其的体外活性。
Eur J Clin Microbiol Infect Dis. 2023 Sep;42(9):1135-1143. doi: 10.1007/s10096-023-04645-2. Epub 2023 Aug 1.

引用本文的文献

1
First Clinical Application of Aztreonam-Avibactam in Treating Carbapenem-Resistant Enterobacterales: Insights from Therapeutic Drug Monitoring and Pharmacokinetic Simulations.氨曲南-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌的首次临床应用：治疗药物监测和药代动力学模拟的见解
J Pers Med. 2024 Nov 30;14(12):1135. doi: 10.3390/jpm14121135.
2
Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against isolates.评估肉汤纸片洗脱法测定头孢他啶/阿维巴坦联合氨曲南对 分离株的药敏结果。
Microbiol Spectr. 2024 Oct 3;12(10):e0095324. doi: 10.1128/spectrum.00953-24. Epub 2024 Sep 3.
3
Practical Application of Aztreonam-Avibactam as a Treatment Strategy for Ambler Class B Metallo-β-Lactamase Producing Enterobacteriaceae.氨曲南-阿维巴坦作为治疗产Ambler B类金属β-内酰胺酶肠杆菌科细菌的治疗策略的实际应用。
Antibiotics (Basel). 2024 Aug 14;13(8):766. doi: 10.3390/antibiotics13080766.
4
Minimum inhibitory concentrations of aztreonam-avibactam, ceftazidime-avibactam and meropenem in clinical isolates of Klebsiella pneumoniae harboring carbapenemase genes.携带碳青霉烯酶基因的肺炎克雷伯菌临床分离株中氨曲南-阿维巴坦、头孢他啶-阿维巴坦和美罗培南的最低抑菌浓度
J Antibiot (Tokyo). 2024 Oct;77(10):706-710. doi: 10.1038/s41429-024-00758-8. Epub 2024 Jul 1.
5
Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.朋友还是敌人？应对多重耐药/广泛耐药革兰氏阴性菌的新型抗菌药物：一项系统综述
Front Microbiol. 2024 May 10;15:1385475. doi: 10.3389/fmicb.2024.1385475. eCollection 2024.
6
Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilli.比较评估多药耐药革兰氏阴性杆菌中阿维巴坦与氨曲南联合体外疗效的检测方法。
Ann Clin Microbiol Antimicrob. 2024 May 25;23(1):47. doi: 10.1186/s12941-024-00708-0.
7
An NDM-Producing Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance.一株产NDM的临床分离株对头孢地尔、头孢他啶-阿维巴坦合剂及氨曲南耐药：迈向泛β-内酰胺耐药的又一步。
Open Forum Infect Dis. 2023 May 17;10(7):ofad276. doi: 10.1093/ofid/ofad276. eCollection 2023 Jul.
8
Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).氨曲南/阿维巴坦对2019年至2021年期间从欧洲、亚洲和拉丁美洲医院收集的大量耐碳青霉烯类肠杆菌科细菌（CRE）的活性。
JAC Antimicrob Resist. 2023 Mar 22;5(2):dlad032. doi: 10.1093/jacamr/dlad032. eCollection 2023 Apr.
9
Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales.评估头孢他啶与阿维巴坦联合使用对肠杆菌科的稀释药敏试验方法。
Microbiol Spectr. 2022 Dec 21;10(6):e0360122. doi: 10.1128/spectrum.03601-22. Epub 2022 Nov 7.
10
Drug development concerning metallo-β-lactamases in gram-negative bacteria.针对革兰氏阴性菌中金属β-内酰胺酶的药物研发。
Front Microbiol. 2022 Sep 15;13:959107. doi: 10.3389/fmicb.2022.959107. eCollection 2022.

本文引用的文献

1
Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales.评估头孢他啶对产超广谱β-内酰胺酶肠杆菌科高度耐药菌株中阿维巴坦/头孢他啶药敏试验的体外影响。
J Antimicrob Chemother. 2021 Mar 12;76(4):979-983. doi: 10.1093/jac/dkaa531.
2
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会关于产超广谱β-内酰胺酶肠杆菌科（ESBL-E）、耐碳青霉烯肠杆菌科（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的治疗指南。
Clin Infect Dis. 2021 Apr 8;72(7):e169-e183. doi: 10.1093/cid/ciaa1478.
3
Antibiotic Susceptibility of NDM-Producing Collected in the United States in 2017 and 2018.2017年和2018年在美国收集的产NDM菌株的抗生素敏感性
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00499-20.
4
Validation of Aztreonam-Avibactam Susceptibility Testing Using Digitally Dispensed Custom Panels.使用数字分配定制面板验证氨曲南-阿维巴坦药敏试验
J Clin Microbiol. 2020 Mar 25;58(4). doi: 10.1128/JCM.01944-19.
5
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.头孢他啶/阿维巴坦与氨曲南联合治疗产NDM-1/OXA-48/CTX-M-15肺炎克雷伯菌感染后的临床结局
J Antimicrob Chemother. 2018 Apr 1;73(4):1104-1106. doi: 10.1093/jac/dkx496.
6
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.氨曲南-阿维巴坦和对照药物对当代（2016 年）临床肠杆菌科分离株的抗菌活性。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01856-17. Print 2018 Jan.
7
Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.2012 年至 2015 年，40 个国家临床实验室分离的肠杆菌科和铜绿假单胞菌对头孢他啶-阿维巴坦的活性。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00472-17. Print 2017 Sep.
8
Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam.从一组经头孢他啶、头孢洛林或氨曲南-阿维巴坦联合检测的耐碳青霉烯类肠杆菌科细菌中鉴定出异常的大肠杆菌PBP 3插入序列。
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00389-17. Print 2017 Aug.
9
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
10
Carbapenem resistance: overview of the problem and future perspectives.碳青霉烯类耐药性：问题概述与未来展望
Ther Adv Infect Dis. 2016 Feb;3(1):15-21. doi: 10.1177/2049936115621709.

2019 年 3 月至 2020 年 12 月，抗生素耐药实验室网络中金属-β-内酰胺酶产生菌的阿兹仑司他-阿维巴坦药敏测试项目。

Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020.

机构信息

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Wadsworth Center, New York State Department of Health, Albany, New York, USA.

出版信息

Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0048621. doi: 10.1128/AAC.00486-21.

DOI:10.1128/AAC.00486-21
PMID:34060895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8284474/
Abstract

Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution. For 64 clinical isolates tested, the MIC and MIC values of aztreonam-avibactam were 0.5/4 μg/ml and 8/4 μg/ml, respectively. Aztreonam-avibactam displayed potent activity against the MBL-producing tested.

摘要

氨曲南-阿维巴坦是一种处于 3 期临床试验阶段的药物组合，建议用于治疗由产金属β-内酰胺酶（MBL）的 引起的严重感染，方法是将头孢他啶-阿维巴坦与氨曲南联合使用。自 2019 年以来，四个抗生素耐药性实验室网络区域实验室通过肉汤微量稀释法提供氨曲南-阿维巴坦药敏试验。对 64 株临床分离株进行检测，结果显示氨曲南-阿维巴坦的 MIC 和 MIC 值分别为 0.5/4μg/ml 和 8/4μg/ml。氨曲南-阿维巴坦对检测到的产 MBL 的 具有强大的 活性。